Everything we've seen

1. ·Sep 14, 3:30 PMstreamnews

   AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long

   AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.

2. ·Sep 14, 3:30 PMstreamnews

   AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears

   Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting statistically significant reductions in moderate-to-severe exacerbations across two trials and across a broad r

3. ·Sep 14, 3:30 PMstreamnews

   Reported Earlier, AstraZeneca And Daiichi Sankyo's Enhertu Cuts Risk Of Disease Progression Or Death By 37.0% Versus Pembrolizumab Plus Chemotherapy In Phase III Trial

   6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapyAstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care

4. ·Sep 14, 3:30 PMstreamnews

   Reported Earlier, AstraZeneca Says Tagrisso Reduces Risk Of Death By 48% Versus Placebo In Overall Stage IB-IIIA Trial Population, With 79% Alive At Eight Years Versus 64%

   Longest survival data ever reported in a global Phase III trial in this settingNew data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages

5. ·Sep 14, 3:30 PMstreamnews

   TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

   WILMINGTON, Del., September 14, 2026--Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.

6. ·Sep 14, 3:30 PMstreamnews

   ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

   WILMINGTON, Del., September 14, 2026--Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-

7. ·Sep 14, 3:15 PMstreamnews

   AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long

   AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.

8. ·Sep 14, 3:15 PMstreamnews

   AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears

   Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting statistically significant reductions in moderate-to-severe exacerbations across two trials and across a broad r

9. ·Sep 14, 3:15 PMstreamnews

   Reported Earlier, AstraZeneca And Daiichi Sankyo's Enhertu Cuts Risk Of Disease Progression Or Death By 37.0% Versus Pembrolizumab Plus Chemotherapy In Phase III Trial

   6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapyAstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care

10. ·Sep 14, 3:15 PMstreamnews

    Reported Earlier, AstraZeneca Says Tagrisso Reduces Risk Of Death By 48% Versus Placebo In Overall Stage IB-IIIA Trial Population, With 79% Alive At Eight Years Versus 64%

    Longest survival data ever reported in a global Phase III trial in this settingNew data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages

11. ·Sep 14, 3:15 PMstreamnews

    TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

    WILMINGTON, Del., September 14, 2026--Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.

12. ·Sep 14, 3:15 PMstreamnews

    ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

    WILMINGTON, Del., September 14, 2026--Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-

13. ·Sep 14, 3:00 PMstreamnews

    AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long

    AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.

14. ·Sep 14, 3:00 PMstreamnews

    AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears

    Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting statistically significant reductions in moderate-to-severe exacerbations across two trials and across a broad r

15. ·Sep 14, 3:00 PMstreamnews

    Reported Earlier, AstraZeneca And Daiichi Sankyo's Enhertu Cuts Risk Of Disease Progression Or Death By 37.0% Versus Pembrolizumab Plus Chemotherapy In Phase III Trial

    6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapyAstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care

16. ·Sep 14, 3:00 PMstreamnews

    Reported Earlier, AstraZeneca Says Tagrisso Reduces Risk Of Death By 48% Versus Placebo In Overall Stage IB-IIIA Trial Population, With 79% Alive At Eight Years Versus 64%

    Longest survival data ever reported in a global Phase III trial in this settingNew data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages

17. ·Sep 14, 3:00 PMstreamnews

    TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

    WILMINGTON, Del., September 14, 2026--Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.

18. ·Sep 14, 3:00 PMstreamnews

    ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

    WILMINGTON, Del., September 14, 2026--Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-

19. ·Sep 14, 2:45 PMstreamnews

    AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long

    AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.

20. ·Sep 14, 2:45 PMstreamnews

    AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears

    Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting statistically significant reductions in moderate-to-severe exacerbations across two trials and across a broad r

21. ·Sep 14, 2:45 PMstreamnews

    Reported Earlier, AstraZeneca And Daiichi Sankyo's Enhertu Cuts Risk Of Disease Progression Or Death By 37.0% Versus Pembrolizumab Plus Chemotherapy In Phase III Trial

    6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapyAstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care

22. ·Sep 14, 2:45 PMstreamnews

    Reported Earlier, AstraZeneca Says Tagrisso Reduces Risk Of Death By 48% Versus Placebo In Overall Stage IB-IIIA Trial Population, With 79% Alive At Eight Years Versus 64%

    Longest survival data ever reported in a global Phase III trial in this settingNew data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages

23. ·Sep 14, 2:45 PMstreamnews

    TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

    WILMINGTON, Del., September 14, 2026--Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.

24. ·Sep 14, 2:45 PMstreamnews

    ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

    WILMINGTON, Del., September 14, 2026--Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-

25. ·Sep 14, 2:30 PMstreamnews

    AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long

    AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.

26. ·Sep 14, 2:30 PMstreamnews

    AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears

    Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting statistically significant reductions in moderate-to-severe exacerbations across two trials and across a broad r

27. ·Sep 14, 2:30 PMstreamnews

    Reported Earlier, AstraZeneca And Daiichi Sankyo's Enhertu Cuts Risk Of Disease Progression Or Death By 37.0% Versus Pembrolizumab Plus Chemotherapy In Phase III Trial

    6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapyAstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care

28. ·Sep 14, 2:30 PMstreamnews

    Reported Earlier, AstraZeneca Says Tagrisso Reduces Risk Of Death By 48% Versus Placebo In Overall Stage IB-IIIA Trial Population, With 79% Alive At Eight Years Versus 64%

    Longest survival data ever reported in a global Phase III trial in this settingNew data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages

29. ·Sep 14, 2:30 PMstreamnews

    TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

    WILMINGTON, Del., September 14, 2026--Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.

30. ·Sep 14, 2:30 PMstreamnews

    ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

    WILMINGTON, Del., September 14, 2026--Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-

31. ·Sep 14, 2:15 PMstreamnews

    AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long

    AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.

32. ·Sep 14, 2:15 PMstreamnews

    AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears

    Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting statistically significant reductions in moderate-to-severe exacerbations across two trials and across a broad r

33. ·Sep 14, 2:03 PMstreamnews

    AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long

    AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.

34. ·Sep 14, 2:03 PMstreamnews

    AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears

    Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting statistically significant reductions in moderate-to-severe exacerbations across two trials and across a broad r

35. ·Sep 14, 1:47 PMstreamnews

    AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long

    AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.

36. ·Sep 14, 1:47 PMstreamnews

    AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears

    Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting statistically significant reductions in moderate-to-severe exacerbations across two trials and across a broad r

37. ·Sep 14, 1:32 PMstreamnews

    AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long

    AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.

38. ·Sep 14, 1:32 PMstreamnews

    AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears

    Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting statistically significant reductions in moderate-to-severe exacerbations across two trials and across a broad r

39. ·Sep 14, 1:15 PMstreamnews

    AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long

    AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.

40. ·Sep 14, 1:15 PMstreamnews

    AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears

    Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting statistically significant reductions in moderate-to-severe exacerbations across two trials and across a broad r

41. ❖Sep 14, 5:39 AMnewsvia finnhub

    Cellectis Pivots to Gene Editing in Major Overhaul

    Cellectis (NASDAQ: CLLS) pivots to in vivo gene editing, extending cash runway to H2 2028. Read pipeline updates on .HEAL-101 & .HEAL-201.

42. ❖Sep 14, 4:46 AMnewsvia finnhub

    Why Is AstraZeneca Stock Trading Higher Today?

    AstraZeneca announced long-term survival data for Tagrisso and Enhertu in lung cancer, alongside breast cancer trial updates.

43. ❖Sep 14, 3:59 AMnewsvia finnhub

    Big Pharma Is Pouring Billions Into China’s Biotechs

    Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.

44. ❖Sep 13, 9:55 PMnewsvia finnhub

    ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

    WILMINGTON, Del., September 14, 2026--Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-

45. ❖Sep 13, 9:47 PMnewsvia finnhub

    TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

    WILMINGTON, Del., September 14, 2026--Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.

46. ❖Sep 13, 9:33 PMnewsvia finnhub

    Reported Earlier, AstraZeneca Says Tagrisso Reduces Risk Of Death By 48% Versus Placebo In Overall Stage IB-IIIA Trial Population, With 79% Alive At Eight Years Versus 64%

    Longest survival data ever reported in a global Phase III trial in this settingNew data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages

47. ❖Sep 13, 9:32 PMnewsvia finnhub

    Reported Earlier, AstraZeneca And Daiichi Sankyo's Enhertu Cuts Risk Of Disease Progression Or Death By 37.0% Versus Pembrolizumab Plus Chemotherapy In Phase III Trial

    6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapyAstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care

48. ❖Sep 13, 6:01 AMnewsvia finnhub

    AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears

    Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting statistically significant reductions in moderate-to-severe exacerbations across two trials and across a broad r

49. ❖Sep 12, 3:19 AMnewsvia finnhub

    AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long

    AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.

50. ❖Sep 11, 6:11 PMnewsvia finnhub

    AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus

    A combination of the company’s breast cancer drug Etcamah did not delay worsening of the disease enough to meet the SERENA-4 late-stage trial’s main goal, AstraZeneca said.

51. ❖Sep 11, 5:01 PMnewsvia finnhub

    AstraZeneca Stock Trips On Unexpected Failure In Breast Cancer

    AstraZeneca stock toppled in late trades Friday after the company's experimental breast cancer treatment failed to pass muster.

52. ❖Sep 11, 4:02 PMnewsvia finnhub

    Jim Cramer Says He Is Not Going to Put His Money on AstraZeneca (AZN)

    Toward the end of the lightning round on September 8, when a caller inquired about AstraZeneca PLC (NYSE:AZN), Mad Money host Jim Cramer commented: Alright, now, AstraZeneca reminds me of a company, it’s not unlike Novartis. I’m a little nervous about it. It’s been missing some of its trials. I don’t think COPD is enough […]

53. ❖Sep 11, 11:19 AMnewsvia finnhub

    Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca

    Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (NYSE:AZN) received a positive boost after their combination of Amgen’s Imdelltra and AstraZeneca’s Imfinzi significantly improved overall survival in a late-stage trial involving patients with extensive-stage small-cell lung cancer. The combination was tested as a maintenance treatment against Imfinzi alone in patients whose disease had not progressed after initial […]

54. ❖Sep 11, 11:17 AMnewsvia finnhub

    MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE

    Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 LOE and drive long-term growth.

55. ❖Sep 10, 8:55 PMnewsvia finnhub

    Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion?

    AstraZeneca plc (NASDAQ:AZN) is exploring whether one of its biggest cancer drugs can work better with a carefully selected partner. A late-stage trial found that combining Tagrisso with Orpathys significantly extended the time patients lived without their disease worsening compared with Tagrisso alone. The study tested the combination as an initial treatment for a specific […]

56. ❖Sep 10, 11:56 AMnewsvia finnhub

    AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study

    Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, potentially broadening both drugs' reach.

57. ❖Sep 10, 11:35 AMnewsvia finnhub

    GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff

    GSK's Specialty Medicines are driving growth, but an approaching HIV patent cliff is pushing the company to accelerate its pipeline.

58. ❖Sep 10, 10:31 AMnewsvia finnhub

    Obesity Market Set for Explosive 27% CAGR Growth by 2036, Fueled by 7 Promising Emerging Therapies | DelveInsight

    The obesity therapeutics market is becoming increasingly concentrated around an Eli Lilly–Novo Nordisk duopoly, with tirzepatide (ZEPBOUND) and semaglutide (WEGOVY) continuing to dominate the US branded treatment landscape. However, the competitive environment is evolving rapidly with the introduction of oral GLP-1 therapies. Novo Nordisk's oral WEGOVY surpassed 5 million cumulative US prescriptions within 30 weeks, while Eli Lilly's FOUNDAYO gained notable momentum among patients initiating ora

59. ❖Sep 10, 8:30 AMnewsvia finnhub

    AstraZeneca's $5bn drug promise is no 'buy' signal for Deutsche

    AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew praise from Deutsche Bank for tozorakimab's lung disease data, but the broker paired its positive assessment with a bearish verdict on the shares. The shares traded at 11,634p, broadly flat, while the bank rated the drugmaker 'sell' with a target...

60. ❖Sep 10, 5:21 AMnewsvia finnhub

    Pfizer: Firing On All Cylinders

    Pfizer's pipeline strength is evident, especially with berobenatide and Vyndamax, providing a bridge over the 2028 LOE trough. Read why PFE stock is a buy.

61. ❖Sep 10, 4:00 AMnewsvia finnhub

    Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors

    Chair of Translational Neuro-Oncology at the University of Manchester, previously a member of the Company's Scientific Advisory Board, elected at the 2026 Annual General MeetingVANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced the appointment of Prof. Petra Hamerlik to its board of directors at the Company’s annual

62. ?Sep 9, 6:02 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 4: close $156.90 < MA150 $183.45 (-14.5%), MA falling, 26.2% off 52w high, vol 0.94× avg

63. ❖Sep 9, 5:48 PMnewsvia finnhub

    Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)?

    On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints […]

64. ❖Sep 9, 2:02 PMnewsvia finnhub

    AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough

    Two Phase 3 victories earned priority review, but approval and launch economics remain ahead.

65. ❖Sep 9, 2:01 PMnewsvia finnhub

    Amgen's Imdelltra Sales Surge 115% as Lung-Cancer Combination Meets Major Goals

    The Imdelltra-Imfinzi combination improved survival and response measures in a 563-patient late-stage lung-cancer trial.

66. ❖Sep 9, 11:56 AMnewsvia finnhub

    ERS 2026: tozorakimab’s groundbreaking exacerbation reduction sets a new bar in COPD

    The focus of this latest data presentation was the drug’s efficacy in reducing moderate and severe exacerbations among COPD patients who continued to experience exacerbations despite inhaled standard-of-care therapy.

67. ❖Sep 9, 11:46 AMnewsvia finnhub

    VERAXA Biotech Designates Raju Willener as CFO

    By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) said it appointed Raju Willener as Chief Financial Officer, having previously served as Director of Corporate Development at Exentis Group AG, before becoming its CFO in 2025. Mr. Willener has more than three decades of international financial leadership experience in global capital markets and all aspects of […] The post VERAXA Biotech Designates Raju Willener as CFO appeared first on ExecEdge.

68. ❖Sep 9, 9:07 AMnewsvia finnhub

    Absci's Billion-Dollar Hair Bet: Why The AI Story Doesn't Add Up

    Absci is rated SELL, as its valuation is highly concentrated on ABS-201 with limited partner revenue and an early-stage pipeline. Click for more on ABSI.

69. ❖Sep 9, 9:00 AMnewsvia finnhub

    AstraZeneca COPD data back Citi's $7b peak sales case

    AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew Citi's backing after tozorakimab trial results, supporting an upside case of at least $7 billion in peak sales, roughly twice consensus. Behind the bullish call, phase III data presented at the European Respiratory Society meeting showed tozorakimab...

70. ❖Sep 9, 6:10 AMnewsvia finnhub

    Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study

    Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (LSE:AZN) said a late-stage study of Imdelltra combined with Imfinzi produced improved outcomes in patients with extensive-stage small-cell lung cancer.

71. ❖Sep 9, 5:48 AMnewsvia finnhub

    Merck pairs ADCs with Keytruda in women’s cancer push

    The drugmaker hopes to move the needle on challenging cancers and shore up its pipeline as it prepares for the Keytruda patent cliff.

72. ❖Sep 9, 4:56 AMnewsvia finnhub

    Jim Cramer: Reliance Is ‘Terrific,’ but He Prefers This Steel Stock

    Cramer avoids AstraZeneca, Joby and Grab; favors Trinity, Nucor over Reliance, and praises Simon Property and Federal Realty.

73. ✓Sep 8, 6:03 PMdecisionacted

    Agent 2 — Adaptive — entry

    Stage 4: close $160.04 < MA150 $183.63 (-12.8%), MA falling, 24.8% off 52w high, vol 1.58× avg

74. ?Sep 8, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 4: close $160.04 < MA150 $183.63 (-12.8%), MA falling, 24.8% off 52w high, vol 1.58× avg

75. ❖Sep 8, 1:08 PMnewsvia finnhub

    Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%

    Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.

76. ❖Sep 8, 12:35 PMnewsvia finnhub

    AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test

    The 563-patient study hit three efficacy endpoints, but investors still lack hazard ratios and regulatory timing.

77. ❖Sep 8, 12:05 PMnewsvia finnhub

    AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) Congress Transcript

    AstraZeneca PLC (AZN) European Respiratory Society (ERS) Congress September 8, 2026 11:00 AM EDTCompany ParticipantsRuud Dobber - Executive Vice-President...

78. ❖Sep 8, 10:41 AMnewsvia finnhub

    Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy

    One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.

79. ❖Sep 8, 10:01 AMnewsvia finnhub

    AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) Congress - Slideshow

    2026-09-08. The following slide deck was published by AstraZeneca PLC in conjunction with this event.

80. ❖Sep 8, 9:00 AMnewsvia finnhub

    IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

    Amgen (NASDAQ: AMGN) today announced landmark results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in overall survival with IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's Imfinzi® (durvalumab) compared to durvalumab alone. This study tested IMDELLTRA as a first-line maintenance treatment for people with extensive stage small cell lung cancer (

81. ❖Sep 8, 9:00 AMnewsvia finnhub

    IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer

    WILMINGTON, Del., September 08, 2026--Positive high-level results from a planned interim analysis of the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) versus IMFINZI alone as a 1st-line maintenance treatment. The trial included patients with extensive-stage small cell lung cancer (ES-SCLC) who had not progressed following standard induction treatment w

82. ❖Sep 8, 8:38 AMnewsvia finnhub

    Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?

    MRK trades near its 52-week high as Keytruda drives growth, while its pipeline and new products offer a path beyond the 2028 patent cliff.

83. ❖Sep 8, 8:28 AMnewsvia finnhub

    AstraZeneca tozorakimab COPD Phase 3 trial results 2026

    The drug reduced flare-ups in a broader patient population than existing COPD biologics, with U.S. approval expected in early 2027

84. ❖Sep 8, 7:50 AMnewsvia finnhub

    Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

    WILMINGTON, Del., September 08, 2026--Full results from the positive Phase III OBERON and TITANIA trials showed that tozorakimab is the first biologic to demonstrate statistically significant and highly clinically meaningful efficacy in reducing moderate and severe exacerbations in a broad population of patients with chronic obstructive pulmonary disease (COPD) still experiencing exacerbations while on inhaled standard of care.1,2 The trials included former and current smokers, and patients acro

85. ❖Sep 8, 7:47 AMnewsvia finnhub

    Astrazeneca Secures FDA Approval for New Breast Cancer Treatment

    AstraZeneca secured FDA approval for its breast cancer drug Etcamah and reported positive Phase 3 trial data for lung cancer and COPD.

86. ❖Sep 8, 5:04 AMnewsvia finnhub

    This Dead Money Sector is Leading the S&P This Year

87. ❖Sep 8, 4:08 AMnewsvia finnhub

    Assessment of the Rheumatoid Arthritis Market 2026-2036 Featuring Rise Therapeutics, Taiho Pharmaceutical, Abbvie, Eli Lilly/Incyte, and AstraZeneca

    Unmet needs in refractory patients, tolerability, access, adherence, and flare prevention create room for innovationDublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. Rheumatoid Arthritis Market Forecast to Reach New Growth Milestones Through 2036, Driven by Targeted Therapies and Expanding Patient Demand The report provides a comprehensive analysis of the rheumatoid

88. ❖Sep 8, 4:03 AMnewsvia finnhub

    Commercial Assessment of the Diabetic Nephropathy Market 2026-2036 Featuring Boehringer Ingelheim, Eli Lilly, Bayer, AstraZeneca, UCB Biopharma, Serodus, and Palatin

    Highlights rising patient prevalence, expanding use of cardio-renal therapies, pipeline innovation, and commercial opportunities across the seven major marketsDublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Diabetic Nephropathy - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The diabetic nephropathy and diabetes kidney disease (DKD) market reached approximately USD 8.80 billion in 2025 across the seven major markets (7MM): the Unit

89. ❖Sep 8, 3:50 AMnewsvia finnhub

    AstraZeneca Announces Tozorakimab Demonstrates Reduction In Participants With Chronic Obstructive Pulmonary Disease In Phase III OBERON, TITANIA Studies

    https://www.astrazeneca.com/media-centre/press-releases/2026/tozorakimab-demonstrated-statistically-significant-highly-clinically-meaningful-reduction-copd-exacerbations-oberon-titania-phase-iii-trials.html

90. ❖Sep 8, 2:17 AMnewsvia finnhub

    Health Care's Next Act: Tailwinds Emerging Across R&D Cycle

    Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation.

91. ❖Sep 7, 10:03 AMnewsvia finnhub

    Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval

    Citi has flagged AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) accelerated approval for Etcamah, known chemically as camizestrant, as a meaningful sentiment driver for the shares. The oral selective oestrogen receptor degrader has been cleared by the US Food and Drug Administration in combination...

92. ❖Sep 7, 8:41 AMnewsvia finnhub

    AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah

    AZN's Etcamah wins accelerated FDA approval for certain advanced breast cancer patients, backed by a 56% risk reduction in progression or death.

93. ❖Sep 7, 7:14 AMnewsvia finnhub

    Evinova and Lothar Medical partner on respiratory device trials

    Evinova's Unified Trial Solution will integrate with Lothar Medical's devices, providing sites and patients connected data.

94. ?Aug 28, 6:02 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 4: close $162.70 < MA150 $184.64 (-11.9%), MA falling, 23.5% off 52w high, vol 0.66× avg

95. ?Aug 26, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 4: close $166.31 < MA150 $184.92 (-10.1%), MA falling, 21.8% off 52w high, vol 1.42× avg

96. ?Aug 26, 6:02 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 4: close $166.31 < MA150 $184.92 (-10.1%), MA falling, 21.8% off 52w high, vol 1.42× avg

97. ?Aug 10, 6:01 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 4: close $161.91 < MA150 $186.93 (-13.4%), MA falling, 23.9% off 52w high, vol 0.95× avg

98. ?Aug 7, 6:00 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 4: close $161.36 < MA150 $187.07 (-13.7%), MA falling, 24.1% off 52w high, vol 0.88× avg

99. ?Aug 7, 6:00 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 4: close $161.36 < MA150 $187.07 (-13.7%), MA falling, 24.1% off 52w high, vol 0.88× avg

100. ?Aug 6, 6:00 PMdecisionconsidered

     Agent 2 — Adaptive — considered

     Stage 4: close $161.04 < MA150 $187.22 (-14.0%), MA falling, 24.3% off 52w high, vol 0.92× avg

101. ?Aug 5, 6:01 PMdecisionconsidered

     Agent 2 — Adaptive — entry

     [not executed — reserve_floor_or_cash] Stage 4: close $161.47 < MA150 $187.38 (-13.8%), MA falling, 24.1% off 52w high, vol 1.71× avg

102. ?Aug 5, 6:01 PMdecisionconsidered

     Agent 1 — Immutable — considered

     Stage 4: close $161.47 < MA150 $187.38 (-13.8%), MA falling, 24.1% off 52w high, vol 1.71× avg

103. ?Aug 4, 6:01 PMdecisionconsidered

     Agent 1 — Immutable — considered

     Stage 4: close $155.61 < MA150 $187.54 (-17.0%), MA falling, 26.8% off 52w high, vol 2.19× avg

104. ?Aug 4, 6:01 PMdecisionconsidered

     Agent 2 — Adaptive — entry

     [not executed — reserve_floor_or_cash] Stage 4: close $155.61 < MA150 $187.54 (-17.0%), MA falling, 26.8% off 52w high, vol 2.19× avg

105. ?Aug 3, 6:00 PMdecisionconsidered

     Agent 1 — Immutable — considered

     Stage 4: close $158.00 < MA150 $187.74 (-15.8%), MA falling, 25.7% off 52w high, vol 5.57× avg

106. ?Aug 3, 6:00 PMdecisionconsidered

     Agent 2 — Adaptive — considered

     Stage 4: close $158.00 < MA150 $187.74 (-15.8%), MA falling, 25.7% off 52w high, vol 5.57× avg

107. ?Jul 28, 6:02 PMdecisionconsidered

     Agent 2 — Adaptive — considered

     Stage 4: close $172.51 < MA150 $188.16 (-8.3%), MA falling, 18.9% off 52w high, vol 2.14× avg

108. ?Jul 28, 6:02 PMdecisionconsidered

     Agent 1 — Immutable — considered

     Stage 4: close $172.51 < MA150 $188.16 (-8.3%), MA falling, 18.9% off 52w high, vol 2.14× avg

109. ✓Jul 28, 6:02 PMdecisionacted

     Agent 9 — Bear Equity — entry

     Stage 4: close $172.51 < MA150 $188.16 (-8.3%), MA falling, 18.9% off 52w high, vol 2.14× avg

110. ?Jul 27, 6:01 PMdecisionconsidered

     Agent 9 — Bear Equity — entry

     [not executed — reserve_floor_or_cash] Stage 4: close $169.73 < MA150 $188.22 (-9.8%), MA falling, 20.2% off 52w high, vol 2.24× avg

111. ?Jul 27, 6:01 PMdecisionconsidered

     Agent 1 — Immutable — considered

     Stage 4: close $169.73 < MA150 $188.22 (-9.8%), MA falling, 20.2% off 52w high, vol 2.24× avg

112. ?Jul 27, 6:00 PMdecisionconsidered

     Agent 2 — Adaptive — considered

     Stage 4: close $169.73 < MA150 $188.22 (-9.8%), MA falling, 20.2% off 52w high, vol 2.24× avg

113. ?Jul 24, 6:00 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $169.07 < MA150 $188.28 (-10.2%), MA falling, 20.5% off 52w high, vol 1.18× avg

114. ?Jul 23, 6:00 PMdecisionconsidered

     Agent 1 — Immutable — considered

     Stage 4: close $168.29 < MA150 $188.37 (-10.7%), MA falling, 20.9% off 52w high, vol 0.82× avg

115. ?Jul 23, 6:00 PMdecisionconsidered

     Agent 2 — Adaptive — considered

     Stage 4: close $168.29 < MA150 $188.37 (-10.7%), MA falling, 20.9% off 52w high, vol 0.82× avg

116. ?Jul 23, 6:00 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $168.29 < MA150 $188.37 (-10.7%), MA falling, 20.9% off 52w high, vol 0.82× avg

117. ?Jul 22, 6:00 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $169.72 < MA150 $188.47 (-9.9%), MA falling, 20.2% off 52w high, vol 0.87× avg

118. ?Jul 21, 6:01 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $169.34 < MA150 $188.54 (-10.2%), MA falling, 20.4% off 52w high, vol 0.73× avg

119. ?Jul 21, 6:00 PMdecisionconsidered

     Agent 1 — Immutable — considered

     Stage 4: close $169.34 < MA150 $188.54 (-10.2%), MA falling, 20.4% off 52w high, vol 0.73× avg

120. ?Jul 21, 6:00 PMdecisionconsidered

     Agent 2 — Adaptive — considered

     Stage 4: close $169.34 < MA150 $188.54 (-10.2%), MA falling, 20.4% off 52w high, vol 0.73× avg

121. ?Jul 20, 6:01 PMdecisionconsidered

     Agent 1 — Immutable — considered

     Stage 4: close $164.52 < MA150 $188.61 (-12.8%), MA falling, 22.7% off 52w high, vol 0.84× avg

122. ?Jul 20, 6:01 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $164.52 < MA150 $188.61 (-12.8%), MA falling, 22.7% off 52w high, vol 0.84× avg

123. ?Jul 20, 6:01 PMdecisionconsidered

     Agent 2 — Adaptive — considered

     Stage 4: close $164.52 < MA150 $188.61 (-12.8%), MA falling, 22.7% off 52w high, vol 0.84× avg